Pathology in United States: Diffuse Large B-Cell Lymphoma – Pipeline Review, H1 2012

• Publication date: February 2013
• Report size: 203 pages

This report provides information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma. 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databas...

This report provides information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma. 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Diffuse Large B-Cell Lymphoma.
- A review of the Diffuse Large B-Cell Lymphoma products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Diffuse Large B-Cell Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Pathology Industry

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global March kets Direct Report Coverage 8
Diffuse Large B-Cell Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diffuse Large B-Cell Lymphoma 10
Diffuse Large B-Cell Lymphoma Therapeutics under Development by Firms 12
Diffuse Large B-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Pre-Clinical Stage Products 24
Comparative Analysis 24
Diffuse Large B-Cell Lymphoma Therapeutics – Products under Development by Firms 25
Diffuse Large B-Cell Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 27
Companies Involved in Diffuse Large B-Cell Lymphoma Therapeutics Development 36
F. Hoffmann-La Roche Ltd. 36
Amgen Inc. 37
Sanofi-Aventis 38
AstraZeneca PLC 39
Eli Lilly and Firms 40
GlaxoSmithKline plc 41
Seattle Genetics, Inc. 42
Takeda Pharmaceutical Firms Limited 43
Millennium Pharmaceuticals, Inc. 44
Pfizer Inc. 45
Teva Pharmaceutical Market Limited 46
Cell Therapeutics, Inc. 47
Genmab A/S 48
Celgene Corporation 49
Incyte Corporation 50
IMMUNOMEDICS, INC 51
Telik, Inc. 52
Pharmacyclics, Inc. 53
Chipscreen Biosciences Ltd 54
Memgen, LLC. 55
Ascenta Therapeutics, Inc. 56
CureTech Ltd. 57
Cylene Pharmaceuticals, Inc. 58
Probiomed S.A. de C.V. 59
PharmaTech International, Inc. 60
Diffuse Large B-Cell Lymphoma – Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 68
RG7159 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Enzastaurin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Cyclophosphamide + Epirubicin + Vincristine + Prednisone - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Revlimid - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Ofatumumab + DHAP - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 76
Pixantrone + Rituximab - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Avastin + R-CHOP - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 79
EPOCH + Rituximab - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 81
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 83
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone + Darbepoetin Alpha - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 85
Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 87
Rituximab + Doxorubicin + Vincristine + Prednisone - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 89
DHAP + Rituximab - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
ICE + RITUXIMAB - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 93
Cyclophosphamide + Vincristine + Prednisone + Epirubicin + Rituximab + G-CSF - Drug Profile 94
Product Description 94
Mechanism of Action 95
R&D Progress 95
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 98
Cyclophosphamide + Prednisone + Epirubicin + Vinblastine + Rituximab + G-CSF - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 101
R-CHOP14 + Darbepoetin Alfa - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 103
Rituximab-HDS - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Bleomycin Sulfate + Rituximab + CHOP Regimen + EPOCH Regimen + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Methotrexate + Mitoxantrone Hydrochloride + Prednisolone + Prednisone + Vincristine Sulfate - Drug Profile 105
Product Description 105
Mechanism of Action 106
R&D Progress 108
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Filgrastim + Carboplatin + Etoposide + Ifosfamide - Drug Profile 109
Product Description 109
Mechanism of Action 110
R&D Progress 111
Lenalidomide - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
PBO-326 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Bortezomib + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 115
Diffuse Large B-Cell Lymphoma Therapeutics – Drug Profile Updates 116
Diffuse Large B-Cell Lymphoma Therapeutics – Discontinued Products 121
Diffuse Large B-Cell Lymphoma Therapeutics - Dormant Products 122
Diffuse Large B-Cell Lymphoma – Product Development Milestones 124
Featured News & Press Releases 124
December 11, 2011: Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma 124
August 23, 2011: Seattle Genetics Initiates Phase II Clinical Trial Of ADCETRIS In CD30-Positive Non-Hodgkin Lymphoma 125
May 17, 2011: Teva And CureTech Announce Positive Data From Phase II Study Of CT-011 126
May 03, 2011: Cell Therapeutics To Re-submit Pixantrone NDA 127
March 21, 2011: Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial In Relapsed/Refractory Diffuse Large B-Cell Lymphoma 128
February 04, 2011: Takeda Announces Publication Of Phase II Trial Results Of Velcade In Journal Of Clinical Oncology 128
December 07, 2010: Pharmacyclics Reports Updated Clinical Results From Phase IA Trial Of PCI-32765 129
September 30, 2010: Avila Initiates Phase I Clinical Study Of AVL-292 For Treatment Of B Cell Cancers And Autoimmune Diseases 130
December 07, 2009: Seattle Genetics Reports Data from SGN-40 (Dacetuzumab) Phase Ib Combination Clinical Trials 131
October 21, 2009: Millennium Initiates Phase II Trial For Diffuse Large B-Cell Lymphoma 131
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 134
Contact Us 134
Disclaimer 134

List of Tables

Number of Products Under Development for Diffuse Large B-Cell Lymphoma, H1 2012 10
Products under Development for Diffuse Large B-Cell Lymphoma – Comparative Analysis, H1 2012 11
Number of Products under Development by Firms, H1 2012 13
Number of Products under Development by Firms, H1 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2012 16
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 20
Comparative Analysis by Late Stage Development, H1 2012 21
Comparative Analysis by Mid Clinical Stage Development, H1 2012 22
Comparative Analysis by Early Clinical Stage Development, H1 2012 23
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 24
Products under Development by Firms, H1 2012 25
Products under Development by Firms, H1 2012 (Contd..1) 26
Products under Investigation by Universities/Institutes, H1 2012 27
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 28
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 29
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 30
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 32
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 33
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 34
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 35
F. Hoffmann-La Roche Ltd., H1 2012 36
Amgen Inc., H1 2012 37
Sanofi-Aventis, H1 2012 38
AstraZeneca PLC, H1 2012 39
Eli Lilly and Firms, H1 2012 40
GlaxoSmithKline plc, H1 2012 41
Seattle Genetics, Inc., H1 2012 42
Takeda Pharmaceutical Firms Limited, H1 2012 43
Millennium Pharmaceuticals, Inc., H1 2012 44
Pfizer Inc., H1 2012 45
Teva Pharmaceutical Market Limited, H1 2012 46
Cell Therapeutics, Inc., H1 2012 47
Genmab A/S, H1 2012 48
Celgene Corporation, H1 2012 49
Incyte Corporation, H1 2012 50
IMMUNOMEDICS, INC, H1 2012 51
Telik, Inc., H1 2012 52
Pharmacyclics, Inc., H1 2012 53
Chipscreen Biosciences Ltd, H1 2012 54
Memgen, LLC., H1 2012 55
Ascenta Therapeutics, Inc., H1 2012 56
CureTech Ltd., H1 2012 57
Cylene Pharmaceuticals, Inc., H1 2012 58
Probiomed S.A. de C.V., H1 2012 59
PharmaTech International, Inc., H1 2012 60
Assessment by Monotherapy Products, H1 2012 61
Assessment by Combination Products, H1 2012 62
Assessment by Stage and Route of Administration, H1 2012 64
Assessment by Molecule Type, H1 2012 67
Diffuse Large B-Cell Lymphoma Therapeutics – Drug Profile Updates 116
Diffuse Large B-Cell Lymphoma Therapeutics – Discontinued Products 121
Diffuse Large B-Cell Lymphoma Therapeutics – Dormant Products 122
Diffuse Large B-Cell Lymphoma Therapeutics – Dormant Products (Contd..1) 123

List of Figures

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2012 10
Products under Development for Diffuse Large B-Cell Lymphoma – Comparative Analysis, H1 2012 11
Products under Development by Firms, H1 2012 12
Products under Investigation by Universities/Institutes, H1 2012 15
Late Stage Products, H1 2012 21
Mid Clinical Stage Products, H1 2012 22
Early Clinical Stage Products, H1 2012 23
Pre-Clinical Stage Products, H1 2012 24
Assessment by Monotherapy Products, H1 2012 61
Assessment by Combination Products, H1 2012 62
Assessment by Route of Administration, H1 2012 63
Assessment by Stage and Route of Administration, H1 2012 64
Assessment by Molecule Type, H1 2012 65
Assessment by Stage and Molecule Type, H1 2012 66

Cancer in World

Iraq Prostate Cancer, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Iraq, World

Cook Islands Prostate Cancer, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Togo Prostate Cancer, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Togo, World

Micronesia( Federated States Of) Prostate Cancer, 60-69 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Cuba Prostate Cancer, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Cuba, World

Pathology in World

Palau Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Cote D`ivoire Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Congo-brazzaville Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Mali Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Mali, World

Trinidad & Tobago Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World